Evidence map›Paper›PMID 41098576›Full record

ArticleACS pharmacology & translational science2025

Antifibrotic Efficacy of a Nintedanib-Peptide Conjugate and Diagnostic Potential of a Fluorescent Companion Probe Targeting α

Kelly Bugatti, Erica Ferrini, Margherita Restori, Costanza Bonfini, Melissa Marchese, Francesca Bianchini, Sara Tomassetti, Andrea Maurizio, Monica Baiula, Lucia Battistini and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS pharmacology & translational science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Kelly BugattiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.
Erica FerriniMolecular Imaging Facility, Experimental Pharmacology & Translational Science Department, Chiesi Farmaceutici S.p.A., 43122 Parma, Italy.
Margherita RestoriDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.
Costanza BonfiniDepartment of Veterinary Science, University of Parma, 43126 Parma, Italy.
Melissa MarcheseDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
Francesca BianchiniDepartment of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, 50134 Florence, Italy.
Sara TomassettiDepartment of Clinical and Experimental Medicine, University of Florence, 50134 Florence, Italy.
Andrea MaurizioDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0009-0002-9389-6522
Monica BaiulaDepartment of Pharmacy and Biotechnology, University of Bologna, 40126 Bologna, Italy.ORCID https://orcid.org/0000-0003-0363-0633
Lucia BattistiniDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID https://orcid.org/0000-0002-5341-5547
Enrico MarcantonioDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.
Claudio CurtiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID https://orcid.org/0000-0002-6117-1503
Monica CiveraDepartment of Chemistry, University of Milan, 20133 Milan, Italy.ORCID https://orcid.org/0000-0001-5171-1062
Laura BelvisiDepartment of Chemistry, University of Milan, 20133 Milan, Italy.ORCID https://orcid.org/0000-0002-3593-2970
Andrea SartoriDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID https://orcid.org/0000-0002-9688-6760
Franco F StellariMolecular Imaging Facility, Experimental Pharmacology & Translational Science Department, Chiesi Farmaceutici S.p.A., 43122 Parma, Italy.ORCID https://orcid.org/0000-0002-8855-7297
Franca ZanardiDepartment of Food and Drug, University of Parma, 43124 Parma, Italy.ORCID https://orcid.org/0000-0001-7451-781X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Idiopathic pulmonary fibrosis (IPF) is a fatal fibrotic pathology currently treated with two antifibrotic drugs, nintedanib and pirfenidone; however, more effective and safer cell-specific therapeutic agents are needed to overcome their limited efficacy and tolerability. αvβ6 integrin is a clinically validated fibrosis biomarker, and several αvβ6-targeted small molecules and positron emission tomography (PET) tracers have recently proven their therapeutic and diagnostic potential in IPF. Surprisingly, αvβ6-targeted and fibrosis-related drug conjugates are still lacking. Two molecular conjugates, namely the previously reported peptide-drug conjugate (PDC)

Indexed as

drug deliveryoptical imagingpeptide–drug conjugatespulmonary fibrosisRGD peptidestargeted therapy

Identifiers

PMID41098576
PMCPMC12519263

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.